Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GPC3-targeted CAR-T cells (Nanjing Drum Tower Hospital)
- Development stage
- Phase 1
- Lead developer
- Nanjing Drum-Tower Hospital
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
GPC3-targeted CAR-T cells (Nanjing Drum Tower Hospital) is an autologous chimeric antigen receptor (CAR) T-cell therapy being investigated for the treatment of advanced hepatocellular carcinoma (HCC). Developed by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School, the therapy utilizes a patient's own T cells that have been genetically engineered to express a CAR specific for Glypican 3 (GPC3). GPC3 is an oncofetal antigen that is highly expressed on the surface of HCC cells but has very limited expression in healthy adult tissues, making it an ideal target for immunotherapy. The treatment involves the infusion of these modified cells, which are designed to recognize GPC3-positive tumor cells and induce a targeted cytotoxic immune response to eliminate the cancer.
- Other names
- GPC3-CAR-TGPC-3-CAR-TGPC 3-CAR-TGlypican-3-targeted chimeric antigen receptor T cellsGlypican3-targeted chimeric antigen receptor T cellsGlypican 3-targeted chimeric antigen receptor T cellsGPC3-targeted CAR-T cells-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolGPC-3-targeted CAR-T cells-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolGPC 3-targeted CAR-T cells-The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on GPC3-targeted CAR-T cells (Nanjing Drum Tower Hospital).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GPC3-targeted CAR-T cells (Nanjing Drum Tower Hospital).